What's new?

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.


Avec EOS, Sofinnova finance pour la seconde fois avec succès le même trio d’entrepreneurs italiens

Paris, France. 20 novembre 2013. Sofinnova Partners, société indépendante de capital risque basée à Paris, annonce la vente de Ethical Oncology Science (EOS), une société de son portefeuille basée à Milan (Italie), spécialisée dans le développement de thérapies pour traiter le cancer, à Clovis Oncology pour une valeur d’entreprise totale de 420 M$ (310 M€).

Selon les termes de l’accord, Clovis Oncology (NASDAQ:CLVS) acquiert EOS en échange d’un paiement initial de 200 M$, qui inclut 190 M$ en actions Clovis (3 713 731 actions) et 10 M$ en cash. Un paiement additionnel de 65 M$ interviendra lors de l’approbation par la FDA aux Etats Unis (Food and Drug Administration) du médicament lucitanib que développe EOS. Suite à l’accord de licence avec Les Laboratoires Servier, Clovis pourra bénéficier de 350 M€ (environ 338 M$) sur la base de la realisation d’objectifs commerciaux et de développement, ainsi que de royalties sur les ventes du lucitanib sur les territories couverts par Servier. Clovis paiera également aux actionnaires de Eos des paiements d’étape pouvant aller jusqu’à 115 M€ supplémentaires (environ 155 M$) sur la base de la réalisation d’objectifs liées à l’accord de licence signé avec Servier en 2012.
Investisseur dès la création en 2006, Sofinnova Partners a continué à financer EOS au cours des années suivantes, a fait venir d’autres investisseurs comme Aescap Venture et Principia SGR et est resté l’actionnaire majoritaire jusqu’à aujourd’hui. La société a été créée par Silvano Spinelli, Gabriella Camboni et Ennio Cavaletti, trois entrepreneurs qui ensemble avaient déjà créée Novuspharma, une spin off de Hoffmann La Roche que Sofinnova Partners a également financée dès son démarrage. Novuspharma s’est introduite en bourse en Italie en 2000 puis a été revendue avec succès à CTI, une entreprise de biotechnologie cotée au Nasdaq. EOS développe de nouvelles thérapies ciblées qui répondent à des besoins médicaux non satisfaits pour les patients atteints de cancer. La société détient les droits exclusifs de développement et de commercialisation (sauf Chine) pour le lucitanib, un inhibiteur de kinase ciblant efficacement à la fois les récepteurs Fibroblast Growth Factor Receptor 1 (FGFR1) et Vascular Endothelial Growth Factor Receptor-1-3 (VEGFR-1-3), dont le profil unique lui confère une activité anti-tumorale spécifique dans les tumeurs sur-exprimant le FGFR1. Le lucitanib vise à traiter le cancer du sein ainsi que d’autres tumeurs dite « FGF-aberrant » ou « angiogenesis-sensitive », telles que par exemple le cancer de la thyroïde. Une étude clinique Phase II est actuellement en cours afin d’explorer de nouvelles possibles indications pour le lucitanib. L’acquisition par Clovis s’inscrit à la suite de l’accord avec Servier sur le développement et la commercialisation du lucitanib. Clovis entend collaborer avec Servier sur le développement clinique du lucitanib et maintenir l’exclusivité des droits aux Etats Unis et au Japon.

“Avec EOS, nous avons l’illustration parfaite d’une des stratégies de Sofinnova qui consiste à financer des serial-entrepreneurs sur la durée. Après la vente de Novuspharma, les trois fondateurs étaient désireux de démarrer une nouvelle aventure et nous étions ravis les soutenir à nouveau ”, déclare Antoine Papiernik, Partenaire Associé chez Sofinnova Partners.

“Après le succès de notre première collaboration, il nous a semblé évident de nous tourner vers Sofinnova lorsque nous cherchions les fonds d’amorçage pour EOS. Sofinnova a joué le rôle d’un véritable partenaire, nous accompagnant dans tous les étapes du développement de la société jusqu’à aujourd’hui ”, poursuit Silvano Spinelli, co-fondateur et PDG de EOS.

“Dans le prolongement de l’accord avec Les Laboratoires Servier en 2012, la vente d’EOS à Clovis va nous permettre de poursuivre le développement clinique du lucitanib avec la perspective à terme d’offrir une alternative thérapeutique innovante pour de nombreux patients ”, déclare Dr. Gabriella Camboni, co-fondatrice et Directeur des opérations de EOS.

Contact presse pour Sofinnova Partners
Anne Rein
+33 (0)6 03 35 92 05

Contact presse pour EOS
Silvano Spinelli
+39 335 80 78 330

A propos de Sofinnova Partners
Sofinnova Partners est une société de capital-risque indépendante basée à Paris. Depuis plus de 40 ans, la
société a financé près de 500 sociétés – start-up, spin-off et opérations de retournement. Elle a accompagné
les plus grands entrepreneurs européens dans le domaine des sciences de la vie. Avec 1,3 milliard d’euros sous
gestion, l’équipe de Sofinnova Partners, reconnue pour sa capacité à aider et à soutenir les entreprises de son
portefeuille de la création à la sortie, a permis l’émergence de leaders sur leurs marchés.

A propos de EOS
EOS (Ethical Oncology Science) est une société de biotechnologie basée à Milan en Italie, qui développe des
thérapies ciblées pour les patients atteints de cancer. EOS a été créée par une équipe d’entrepreneurs
expérimentée bénéficiant d’une solide expertise dans le domaine de l’oncologie. Fondée en juin 2006 par
Silvano Spinelli et Gabriella Camboni, la société a financé au démarrage et ultérieurement par ses fondateurs
et le fonds Sofinnova Partners. Pour en savoir plus, consultez www.eosmilano.com/.

A propos de Clovis Oncology
Clovis Oncologyest une société de biopharmacie spécialisée dans le développement de traitements anticancéreux
aux Etats Unis, en Europe et sur les autres marché à l’international. Clovis Oncology est basée à
Boulder, Colorado (USA) et dispose de bureaux à San Francisco, Californie (USA) et à Cambridge (Royaume
Uni). Pour en savoir plus, consultez www.clovisoncology.com


Funds to be used to progress viral vaccine pipeline and to explore applications in cancer immunotherapy

VIENNA, AUSTRIA, November 4, 2013 – Hookipa Biotech AG, a company pioneering a new class of vaccines, today announced that it has raised €20 million ($27.5 million) in a series B equity financing. Existing investors Sofinnova Partners and Forbion Capital Partners led the financing with three new investors, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners joining the round.

Dr. Katherine Cohen, Chief Executive Officer of Hookipa Biotech said: “We have made very substantial progress in the last two years and are delighted to have the support of a highly experienced syndicate of venture investors. I would like to thank our initial investors for their strong confidence in Hookipa and I look forward to working with our new investors as we enter into the exciting next stage of development.”

Hookipa has developed Vaxwave®, a novel and proprietary viral vector platform with exquisite capacity for the stimulation of antibody and CD8+ T cell immunity. The Company’s lead product candidate based on this platform, HB101, is a vaccine against cytomegalovirus (CMV) that is currently in advanced pre-clinical development and testing. The new investment will be used to progress HB101 into Phase I clinical testing and to further industrialize Vaxwave® technology, both for partnering and for building a robust product pipeline in the area of infectious diseases and cancer.

Hookipa’s Vaxwave® technology exhibits great potential for cancer immunotherapy, since Vaxwave® vectors are not inhibited by anti-vector immunity and can be repeatedly administered for stimulating potent CD8+ T cell responses against tumor targets. The series B financing will thus also be used to explore applications for novel cancer therapies.

Graziano Seghezzi, Partner at Sofinnova Partners, the founding investor of Hookipa Biotech, commented: “Since Sofinnova’s seed investment in early 2011, Hookipa has developed from a scientific concept into an innovative early-stage vaccine company. Dr. Cohen’s decisive leadership has been instrumental in rapidly assembling a team of experienced vaccine specialists that have made great progress with the Vaxwave® technology. The strength and diversification of the investors in this Series B syndicate is testament to the potential of the technology and the abilities of the team. I am looking forward to continuing to work with Dr. Cohen and the board to successfully progress Hookipa through its next phase of growth.”

The Company also welcomes Dr. Frank Kalkbrenner from the Boehringer Ingelheim Venture Fund as a new member of the company’s Supervisory Board and Dr. Yuji Iizawa from Takeda Ventures and Dr. Markus Hosang from BioMedPartners as Observers. “We believe the Vaxwave® technology is a ground-breaking platform with potential not only as a prophylactic and therapeutic vaccine in infectious diseases but also as a potential therapeutic approach in the field of oncology. I am pleased to be joining the board together with two seasoned early stage investors, Forbion and Sofinnova, and look forward to working with the experienced team at Hookipa Biotech” commented Dr. Kalkbrenner.

This financing brings the total equity finance raised by Hookipa to €27.5 million. It announced a series A investment of €7 million in October 2011.                                                                                                                                  


This Proof of concept study aims to capitalize on DBV’s safe and non-invasive technology and Inserm’s unique expertise to address refractory Hemophilia A, a severe orphan disease with no cost-effective and convenient treatment today available to patients

BAGNEUX, FRANCE, October 22nd, 2013 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a
new standard in the treatment of allergies, announced today that it has entered into a research collaboration with Institut
national de la Santé et de la recherche médicale, Inserm and Inserm Transfert, to investigate the effect of epicutaneous
delivery of recombinant Factor VIII (FVIII) protein via Viaskin in an animal model of hemophilia A. DBV and Inserm are
teaming up to combine the Viaskin® technology and a world-class expertise in hemophilia A to develop a potential standard
of care for refractory hemophilia A patients, by providing a cost-effective, and non-invasive treatment.

Dr. Sébastien Lacroix-Desmazes, CNRS (Inserm Team UMRS 872, Immunopathology and Therapeutic Immuno-
Intervention), said, “Preventing the immune response to therapeutic proteins upon induction of tolerance is the approach of
choice for patients with hemophilia A. To date, the only strategy to induce tolerance to FVIII in patients who have developed
anti-FVIII antibodies consists in flooding the immune system with enormous amounts of FVIII every day, for periods that can
extend up to several months or years. This obviously faces issues with patients’ compliance and treatment costs. Being able
to induce FVIII-specific tolerance in hemophilia A patients using low doses of antigen, such as is the case with the Viaskin
delivery system, would drastically improve the life of alloimmunized hemophilia A patients and solve a crucial societal

Dr. Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said, “The establishment of a partnership with Dr.
Sebastien Lacroix-Desmazes and Inserm, with their extensive expertise in Hemophilia A, can potentially open a new path for
Viaskin to become the future of hemophilia A treatment as a non-invasive, prophylactic alternative against an alloimmune
response to therapeutic Factor VIII.” Dr. Pierre-Henri Benhamou concluded: “This research should reinforce the relevance of
the Viaskin® platform, as a technology enabling deep and durable modulation of inappropriate immune responses.”

The protective effect conferred by the immunological response induced by epicutaneous immunotherapy using Viaskin®
will be tested at the humoral level, and is expected to induce tolerance to FVIII in mice with severe hemophilia A. The DBVInserm
research collaboration will last 12 months. Different mice cohorts will be treated with Viaskin containing the FVIII
protein versus placebo for 45 days. After 45 days, all mice will be subject to a protocol of replacement therapy for 4 weeks.
The levels of anti-FVIII IgG and of FVIII inhibitors will then be assessed by immunological and functional assays. Various
approaches have investigated treatments aimed at inducing tolerance to exogenous FVIII in hemophilic mice. Through the
Viaskin platform, DBV Technologies has developed a first-in-class approach to deliver antigens of choice to immunosensitized
organisms as a method to induce antigen-specific tolerance, and in this case, tolerance to therapeutic FVIII in
hemophilia A.

About Hemophilia A
Hemophilia A is a rare X chromosome-linked recessive hemorrhagic disorder that affects one individual out of 5,000—
10,000. Genetic abnormalities in the gene encoding FVIII result in the absence of production of FVIII or in the production of
defective FVIII molecules. In up to 30% of the patients, replacement therapy is complicated by the occurrence of anti-drug
antibodies, referred to as inhibitory anti-FVIII antibodies (or FVIII inhibitors), that preclude the use of FVIII as treatment.
Inhibitory anti-FVIII antibodies are of the IgG isotypes, and mostly part of the IgG1 and IgG4 subclasses. Mortality is high
and ranging between 12.5% and 22%, usually because of fatal hemorrhage.

About Inserm
Understand and improve human health
Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and technological institute
which operates under the joint authority of the French Ministry of Health and French Ministry of Research.
As the only French public research institute to focus entirely on human health, in 2008 Inserm took on the responsibility for the
strategic, scientific and operational coordination of biomedical research. This key role as coordinator comes naturally to Inserm thanks to
the scientific quality of its teams and its ability to conduct translational research, from the laboratory to the patient’s bed.
In April 2009, national coordination was strengthened by Aviesan, the Alliance nationale pour les sciences de la vie et de la santé (French
National Alliance for Life and Health Sciences), which Inserm co-founded with other research institutes and the Conférence des
présidents d’université (Association of University Presidents).

About DBV Technologies
DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly
increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major
unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an
allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a
treatment that seeks to improve the patient’s tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in
the event of accidental exposure to the allergen. The company’s significant development program has taken this revolutionary method
through to the industrial stage in Europe, initially. The product’s clinically proven safety of use enables the application of effective
desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies
is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products:
Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the
US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite
allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares
are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

CAUTION: Viaskin® is not approved for sale in the USA.

Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Company’s management strategy, current
views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance
or events to differ materially from those anticipated herein. Furthermore, the Research and Development process involves several stages
each of which involve the substantial risk that the Company may fail to achieve its objectives and be forced to abandon its efforts with
regards to a product in which it has invested significant sums. Therefore, the Company cannot be certain that favorable results obtained
during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to
demonstrate the safe and effective nature of the product concerned. DBV technologies’ business is subject to the risk factors outlined in
its registration documents filed with the French Autorité des Marchés Financiers.

DBV Contacts
DBV Technologies
David Schilansky
Chief Financial Officer
Tél. : +33(0)1 55 42 78 75

US & UK investors
The Trout Group
Investor Relations
Alan S. Roemer
Tél. : +1 (646) 378-2945

French investors
Financial Communication and investor relations
Emmanuel Huynh / Valentine Brouchot
Tél. : +33(0)1 44 71 94 94
US press & media
Ronald Trahan Associates Inc.
Press relations
Ronald Trahan, APR
Tél. : +1 508 359 4005
Inserm Contacts
Tel. : +33(0)1 44 23 60 97

  • Stallergenes pourra exercer une option de développement et de commercialisation sur un nouveau produit dans l’allergie au pollen de bouleau 
  • DBV est éligible à des paiements d’étape ainsi que des redevances sur les ventes de Stallergenes  
  • Stallergenes acquiert une participation dans DBV 


ANTONY et BAGNEUX, France, le 18 octobre 2013 – Stallergenes S.A. (Euronext Paris : GENP), leader mondial de l’immunothérapie allergénique, et DBV Technologies (Euronext Paris : DBV), créateur du Viaskin®, une nouvelle référence dans le traitement de l’allergie, ont annoncé avoir signé un accord de recherche et de développement pour la mise au point d’un nouveau traitement de l’allergie au pollen de bouleau. Cette collaboration est le premier accord s’inscrivant dans le cadre du partenariat entre les deux sociétés dédié au développement de traitements innovants dans le domaine des allergies respiratoires. L’accord signé aujourd’hui permettra d’associer l’expertise mondialement reconnue de Stallergenes dans le domaine des allergies respiratoires à la nouvelle technologie de délivrance épicutanée de DBV, Viaskin®, permettant de moduler la réponse immunitaire.


Pour télécharger la version française du communiqué de presse, cliquez sur le lien:
Stallergenes et DBV Technologies signent une collaboration de recherche


List Recognizes the Top Private Companies in Clean Technology
Amsterdam, the Netherlands – October 10, 2013 Today Cleantech Group, a global market intelligence and consulting firm announced that Avantium, is named in the prestigious 2013 Global Cleantech 100. This is the fourth year in a row that Avantium is named in this unique list, in which the promise of private clean technology companies from all around the world is highlighted. The Cleantech Group focuses on those companies which the players in the market feel are currently the most likely to make the most significant market impact over the next 5-10 years.
―This is our fourth consecutive year to be named in the Global Cleantech Top 100. We are very pleased that the jury confirms our potential to change the world with our YXY technology to produce PEF. It is our goal to make PEF the next generation plastic. Avantium was listed in the Global Cleantech 100 in 2010 for the first time, and our progress has accelerated since that period. We established partnerships with The Coca-Cola Company, Danone, and ALPLA. These industry leaders joined Avantium in developing and commercializing PEF bottles for major consumer markets. We have successfully scaled our YXY technology from lab to pilot plant scale. Our 100% biobased PEF bottles perform superiorly compared to today’s bottles at competitive costs. Being listed in the Global Cleantech 100 is a great recognition of our progress at an important time in the development of our company‖ said Tom van Aken, CEO of Avantium.
The list is derived from Cleantech Group’s own data and research, combined with the weighted qualitative judgments of hundreds of nominations, and the viewpoints of a global 90-person expert panel. This panel was drawn principally from leading financial investors and representatives of multi-national corporations, located in Asia, Europe, and North America. This diversity results in a list of companies that command a broad base of respect and support from many important players within the global cleantech innovation ecosystem. To qualify for the list, companies must be independent, for-profit, cleantech companies that are not listed on any major stock exchange.
―The Global Cleantech 100 is a natural extension of our vision to help corporations and investors connect with innovation around the world,‖ said Sheeraz Haji, CEO of Cleantech Group. ―This list celebrates inspiring entrepreneurs, and serves as the industry standard on gauging where innovation is headed across key sectors.‖
This year 5,864 companies from 60 countries were nominated. These companies were weighted and scored to create a short list of 300 companies. Vital information on these short-listed companies—including key data from Cleantech Group’s i3 platform—was presented to the expert panel for final input. The end result was 100 companies from 18 countries.

About Cleantech Group
Cleantech Group helps clients accelerate sustainable innovation. The company’s i3 platform allows subscribers to discover companies and explore cleantech trends strategically with proprietary real-time data. Cleantech Forums bring together thought leaders and innovators in the cleantech and sustainability ecosystem. The company’s advisory services leverage expertise in designing and
executing corporate strategies for sustainable growth and innovation sourcing. Details at www.cleantech.com
For more information about Cleantech Group, please contact Millen Paschich: tel: +1 (415) 233 9712, email: media-services@cleantech.com.

About Avantium
Avantium is a leading technology company specialized in the area of advanced high-throughput R&D. The company develops and commercializes YXY – the brand name for its technology platform to catalytically convert plant based carbohydrates into chemical building blocks like Furanics and Levulinics. These chemical building blocks can be applied for making green materials with superior product properties at competitive pricing. Currently the focus of the YXY technology platform is on a building block called FDCA, (2,5- furandicarboxylic acid). FDCA can be polymerized together with ethylene glycol (EG) to form PEF (Polyethelyne Furanoate), which is Avantium’s lead application. Combined with the significant reduction in carbon footprint, PEF fulfills key criteria to become the next generation biobased plastics for bottles, film and fibers. PEF for example has gas barrier to oxygen, carbon dioxide and water is superior to PET, leading to longer product shelf life and offering the potential for light weighting of packages. Avantium has demonstrated the value and commercial potential of its unique technology by collaborating with leading companies in the energy and chemical industries. Avantium offices and headquarters are based in Amsterdam, the Netherlands, and Avantium is running an YXY pilot plant in Geleen, the Netherlands.
For more information about Avantium, please contact Mariette Hoogendoorn: tel: +31 (0)20 5868010, email: info@avantium.com.


Minneapolis, Oct. 1, 2013 – BioAmber Inc. (NYSE: BIOA) announced today a payment to Cargill for achieving the final milestone in their development agreement, under which BioAmber has exclusively licensed the Cargill yeast technology for succinic acid production. Completion of this milestone signals that the succinic acid producing yeast has met performance expectations. BioAmber began work in August 2013 on a 30,000 MT plant in Sarnia, Ontario, and has engineered the facility to operate with this proprietary yeast.
« This milestone achievement is the culmination of three years of joint development with Cargill. We licensed this yeast in 2010 because we strongly believed it is the best technology platform in the industry for making organic acids, and because Cargill has experience in the development and commercialization of organic acids that strengthened our succinic acid program, » said Jim Millis, BioAmber’s Chief Technology Officer.
« BioAmber and Cargill’s collaboration has been successful and our yeast technology has proven effective for making succinic acid. We look forward to BioAmber commercializing the yeast when it brings on line its bio-succinic acid facility in Sarnia, » said Gary Folkert, Cargill’s Biotechnology Director of Licensing.
« Our proprietary technology platform has been significantly strengthened with the Cargill yeast. This is an important milestone and we plan to continue to work with Cargill to develop alternative feedstock options for our succinic acid platform and to bring to market our adipic acid yeast platform, which we have also licensed exclusively from Cargill, » said Jean-Francois Huc, BioAmber’s Chief Executive Officer.

About BioAmber
BioAmber (NYSE and EURONEXT Paris: BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products. For more information, visit www.bio-amber.com.

About Cargill
Cargill is an international producer and marketer of food, agricultural, financial and industrial products and services. Founded in 1865, the privately held company employs 140,000 people in 65 countries. Cargill helps customers succeed through collaboration and innovation, and is committed to applying its global knowledge and experience to help meet economic, environmental and social challenges wherever it does business. For more information, visit www.cargill.com.


La Motte-Fanjas, France, Sept. 27, 2013 / – Inauguration of large-scale, onsite system for both generating hydrogen by electrolysis of water and storing it in a safe, solid form
McPhy Energy, a leading developer and manufacturer of solid state hydrogen storage, presented today the world’s first system coupling an industrial-scale hydrogen generator with a 100 kg solid hydrogen storage unit. The demonstration, which showed the results of the first phase of the French PUSHY program, was given at the company’s headquarters in La Motte-Fanjas, in the department of the Drome,France. While such systems enable the supply of onsite hydrogen for industry, they also mark a world premiere in the transition to renewable energies, enabling approaches such as « power-to-gas » and hydrogen mobility to become both technical and commercial realities.

The McPhy Energy technology for storing hydrogen in the form of hydrides is a safe, low-pressure, high-density solution.
The generator, which produces hydrogen through the electrolysis of water, is manufactured by McPhy Italy and powered by 60 KW of electricity from the local electrical grid. The demonstrator shown today can produce 12m[3]of hydrogen per hour. The gas is then stored in McPhy’s HDS 100 system, which is based on magnesium hydride technology developed and manufactured by McPhy Energy in La Motte-Fanjas, France.
The system inaugurates the first commercial product line for onsite industrial hydrogen users worldwide. This first model, which has a storage capacity of 100 kg (for an energy content of 3.3 MWh), is the first in a commercial range reaching up to 500 kg of stored hydrogen (16.5 MWh).
It enables traditional hydrogen logistics (high-pressure delivery) to be replaced with production that is located at the point of use and aligned with demand. This ambitious project, funded by BPI France (formerly OSEO/ISI) was developed in an industrial consortium lead by McPhy Energy, with the CEA (the French Atomic & Alternative Energy Agency) and the company WH2.
« The pilot presented today at our manufacturing site in La Motte-Fanjas is the first deliverable of the PUSHY project. In 2014, it will be followed by a demonstration of hydrogen production by hydroelectric energy, for the storage and exploitation of renewable energies inFrance as in Europe and across the globe, » said Pascal Mauberger, CEO of McPhy Energy. « With the deployment of renewable energies, storage requirements are substantial, and solutions are needed to respond to those needs. That is the objective of this demonstrator model, which marks the beginning of a complete line of groundbreaking products. »

About McPhy Energy
McPhy Energy S.A., which is headquartered near Grenoble, France, develops and manufactures innovative and safe hydrogen technologies. Besides solid-state storage of hydrogen based on metal hydrides, McPhy is consistently expanding activities in on-site generation of hydrogen by means of water electrolysis. With the acquisition of PIEL (Italy) in early 2013, McPhy now has a global installed base of over 3000 systems. For three consecutive years, McPhy has been listed in the « Global CleanTech 100 » group of companies and is one of the « Top 5 CleanTech France » enterprises. The Group has manufacturing sites in France and Italy.


London, September 24th 2013. Synthace, the applied synthetic biology company developing high value chemical and biological products, announces that it has closed a funding round raising £1.3 Million. Sofinnova Partners’ Green Seed Fund led the financing, joined by a syndicate of angel investors.
Synthace is applying its world leading platform of technologies to rapidly engineer and optimise novel biological systems for the production of specialty chemicals and biological products. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and novel molecular biology tools. The company’s platform is broadly applicable across multiple industry sectors, including chemicals, healthcare, energy and agriculture, and has the potential to create as yet uncharted markets and opportunities.
Tim Fell, CEO of Synthace, commented: « We are delighted to have attracted Sofinnova Partners’ Green Seed Fund and see this funding as a very strong validation of our company, technology and commercial focus. It will allow us to demonstrate production of our first chemical products at scale, prior to forming partnerships within the chemicals industry to take them to market.”
Joško Bobanović, Partner at Sofinnova Partners responsible for the fund, added: « Synthace offers a unique combination of a revolutionary technical platform, entrepreneurial and visionary team, developing advanced products for extremely large markets. Green Seed Fund focuses on European investments in renewable chemistry and has recognised Synthace as one of the leaders in this sector offering, in a way, version 2.0 of synthetic biology application.”

For further details, please contact:
Tim Fell, CEO Synthace Tel: + 44 (0) 20 3642 1350

Notes to Editors:
Synthace is the UK’s first dedicated synthetic biology company with a world leading platform of technologies for the rapid engineering and optimisation of novel biological production systems. A spin out of University College London, Synthace harnesses the ability of micro-organisms to produce complex, high-value chemical and biological products from sustainable and renewable feedstocks. In addition to equity funding, the company has received a £500,000 Technology Strategy Board award entitled ‘Rapid Engineering of Cellular Factories’, in collaboration with University College London and University of Manchester. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is initially focused towards applications in the production of specialty chemicals.
More information is available at www.www.synthace.com
Sofinnova Partners is an independent venture capital firm based in Paris, France. For more than 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside Europe’s key entrepreneurs in the Life Sciences industry. With €1.3 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit. sofinnova.social-unit.fr


Paris, France, 29 août 2013. Sofinnova Partners, société de capital-risque basée à Paris, a mené le financement de Série A qui a permis à ObsEva SA, une société biopharmaceutique basée en Suisse et spécialisée en médecine de la reproduction féminine, de lever 32M CHF (25,6M EUR). Pour ce premier tour de financement, Sofinnova Partners a été rejoint par deux co-investisseurs, Sofinnova Ventures et Novo A/S.

ObsEva est spécialisée dans le traitement de la menace d’accouchement prématuré. La société a été cofondée en novembre 2012 par Ernest Loumaye, MD, PhD, un serial entrepreneur que Sofinnova Partners a déjà accompagné avec succès dans PregLem, une société spécialisée en médecine de la reproductionet plus particulièrement le traitement du fibrome utérin. PregLem a été acquise en 2010 par Gedeon Richter pour 445M CHF (361M EUR). L’équipe dirigeante d’ObsEva est pilotée par ses deux co-fondateurs, Ernest Loumaye, Directeur Général, et André Chollet, PhD, Directeur Scientifique.

Simultanément à l’opération de financement, ObsEva a signé un accord de licence mondial avec Merck Serono pour développer et commercialiser certains de leurs produits dans le domaine de l’obstétrique. Dans le cadre de cet accord, Merck Serono a acquis une participation minoritaire au capitald’ObsEva. Le financement va permettre d’accélérer le développement de ces produits qui ont le potentiel d’être des « best-in-class ». En combinant un rationnel biologique solide à un profil pharmaceutique différenciant, ObsEva est ainsi parfaitement positionné pour développer une nouvelle classe de médicaments capables d’apporter aux patientes des solutions de rupture dans la menace d’accouchement prématuré, un domaine médical où il existe un important besoin clinique à combler.

Rafaèle Tordjman, MD, PhD, Partenaire Associée chez Sofinnova Partners, déclare : « Au fil des ans, nous avons développé des liens solides avec Ernest Loumaye. Dans la continuité du succès de PregLem, Sofinnova Partners a financé l’amorçage d’ObsEva. Nous sommes ravis de continuer à soutenir une équipe d’une telle qualité et favoriser le développement d’une nouvelle génération de thérapies pour traiter la menace d’accouchement prématuré ». Ernest Loumaye, PDG, poursuit : « ObsEva répond à des besoins essentiels aujourd’hui encore insatisfaits car les thérapies existantes pour traiter la menace d’accouchement prématuré demeurent limitées en termes d’efficacité ou de sécurité. Aujourd’hui, nous estimons que le coût lié à la menace d’accouchement prématuré est autour de 27 milliards de dollars par an aux Etats Unis. Les produits que nous développons devraient permettre d’améliorer radicalement les options thérapeutiques proposées à des millions de femmes ».

A propos de Sofinnova Partners
Sofinnova Partners est une société de capital-risque indépendante basée à Paris. Depuis plus de 40 ans, la société a financé près de 500 sociétés – start-up, spin-off et opérations de retournement. Elle a accompagné les plus grands entrepreneurs européens dans le domaine des sciences de la vie. Avec 1,3 milliard d’euros sous gestion, l’équipe de Sofinnova Partners, reconnue pour sa capacité à aider et à soutenir les entreprises de son portefeuille de la création à la sortie, a permis l’émergence de leaders sur leurs marchés. sofinnova.social-unit.fr

A propos d’ObsEva SA
ObsEva est une société biopharmaceutique basée en Suisse spécialisée dans le développement des traitements innovants dans le domaine de la reproduction féminine. ObsEva s’intéresse particulièrement au traitement de la menace d’accouchement prématuré. ObsEva a été créée en 2012 par Ernest Loumaye MD, PhD et André Chollet PhD. Ernest Loumaye est un spécialiste de la médecine reproductrice féminine avec une expérience de plus de 20 ans dans l’industrie biopharmaceutique. Il a précédemment co-fondé et dirigé PregLem. André Chollet est un spécialiste de la chimie médicale et pharmaceutique, fort d’une expérience de plus de 30 ans dans le secteur, notamment chez Biogen, GSK et Merck Serono. www.obseva.com